🚨#Tweetorial alert🚨- brought to you by @KIReports@ISNkidneycare#NephTwitter
Not all preeclampsia (PE) is the same. New data on isolated PE vs PE-HELLP syndrome—and why close monitoring matters for patients' cardiovascular and kidney health
https://t.co/WNpxQeDJEg
Is citrate with HD completely benign? We use it all the time in HD and assume it is but this study is giving some second thoughts. Read a great summary from @DrAkshayaJ
1/ Hey #NephX! 👋
We’re back with a fresh #Xtorial from KIReports
Citrate dialysate is often viewed as a friend in dialysis : it chelates Ca, and inhibits Ca/Phos crystallization, But what if the effect on the vessel wall is not so simple?
https://t.co/0Kf2DgxL4i
1/ Hey #NephTwitter! 👋
We’re back with a fresh #Xtorial
🧵Can we finally target the disease, not just the proteinuria in recurrent IgAN after kidney transplantation?
Here's a study answering the question.
📚Read our thread to know more!
@ISNkidneycare@ISNeducation@DrAkshayaJ
2/🚨 Our topic🚨: A Comprehensive Framework for Kidney Function Assessment: Summary of the NIDDKD Reimagining Kidney Function Assessment Workshop.
There are no conflicts of interest. #MedSky#NephSky#MedTwitter#nephtwitter@ISNkidneycare
Article 👉https://t.co/zoAlV8jV7t. .
CKD causes significant morbidity & mortality among children w/heart failure. Read this Original Article on heart-kidney transplant outcomes compared to heart-only transplants in children w/non-dialysis-dependent advanced CKD.
https://t.co/qoDY5yEj4U
🧵 New #Tweetorial Drop! 🧵
1/ Hey #NephTwitter! 👋
We’re back with a fresh #XTorial from @KIReports, this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭
Thoughts about Wegovy vs Zepbound for MACE Reduction? #MedTwitter#NephTwitter
Finding:
-Semaglutide showed 29% reduction
Limits:
-Small # of MACE
-Retrospective
Implications:
-Wegovy may be better for those with ASCVD
-Does GIP have any CV benefits?
https://t.co/LLZ5cKUk1K